US 11,690,818 B2
Drug containing liver targeting specific ligand and thyroid hormone receptor agonist
Kunyuan Cui, Xiamen (CN)
Assigned to KYLONOVA (XIAMEN) BIOPHARMA CO., LTD., Xiamen (CN)
Appl. No. 17/298,740
Filed by KYLONOVA (XIAMEN) BIOPHARMA CO., LTD., Xiamen (CN)
PCT Filed Dec. 2, 2019, PCT No. PCT/CN2019/122318
§ 371(c)(1), (2) Date Jun. 1, 2021,
PCT Pub. No. WO2020/108657, PCT Pub. Date Jun. 4, 2020.
Claims priority of application No. 201811452803.5 (CN), filed on Nov. 30, 2018.
Prior Publication US 2022/0054443 A1, Feb. 24, 2022
Int. Cl. A61K 31/198 (2006.01); A61P 1/16 (2006.01); A61K 47/54 (2017.01)
CPC A61K 31/198 (2013.01) [A61K 47/54 (2017.08); A61K 47/545 (2017.08); A61K 47/548 (2017.08); A61K 47/549 (2017.08); A61P 1/16 (2018.01)] 4 Claims
OG exemplary drawing
 
1. A compound containing a liver targeting specific ligand and a thyroid hormone receptor agonist in the structure, wherein the liver targeting specific ligand X is connected to the thyroid hormone receptor agonist T sequentially through a branched chain L containing a structure for stabilizing steric hindrance, a linker B and a linking chain D, and the compound is represented by Formula (I) of
(X-L)n-B-D-T
wherein n is 3, Formula (I) has a structure as shown below:

OG Complex Work Unit Chemistry
the compound has one of the structures shown in Kylo-0101 to Kylo-0103:

OG Complex Work Unit Chemistry